Horner's SD After Thoracic Epidural Block

NCT ID: NCT02130739

Last Updated: 2014-05-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

450 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-09-30

Study Completion Date

2014-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study prospectively evaluates the incidence of Horner's syndrome after thoracic epidural anesthesia following continuous thoracic epidural analgesia for mastectomy. The incidence was 1.36% and the mechanism of Horner's syndrome was cephalic spread of the local anesthetic.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Transient Horner's syndrome has been recognized rare complication of epidural anesthesia and the incidence is not exactly well-known in thoracic epidural anesthesia. Therefore, this study prospectively evaluates the incidence of Horner's syndrome after thoracic epidural anesthesia following continuous thoracic epidural analgesia for mastectomy.

Six hundred thirty three Patients, who scheduled for mastectomy with/without breast reconstruction, were eligible for this prospective observational study from September 2010 to December 2013. Thoracic epidural anesthesia performed using 0.375% or 0.5% ropivacaine 15mL followed by sedation consisting of propofol without muscle relaxation. After the operation, thoracic epidural analgesia continued; supplemented by a continuous epidural infusion of ropivacaine 0.15%, 2 ml/h with fentanyl 8mcg/h. At 1 hour, 2hour, 1 day, 2 day and 3 day after the operation, postoperative surveillance consisted of the occurrence of symptoms of Horner's syndrome (miosis, ptosis, and hyperemia) were performed by anesthesiologists.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Horner's Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

thoracic epidural anesthesia

thoracic epidural anesthesia following continuous thoracic epidural analgesia for mastectomy

thoracic epidural anesthesia

Intervention Type PROCEDURE

thoracic epidural anesthesia following continuous thoracic epidural analgesia for mastectomy

mastectomy

Intervention Type PROCEDURE

mastectomy with/without breast reconstruction

Ropivacaine

Intervention Type DRUG

Thoracic epidural anesthesia performed using 0.375% or 0.5% ropivacaine

Propofol

Intervention Type DRUG

Thoracic epidural anesthesia performed followed by sedation consisting of propofol

Fentanyl

Intervention Type DRUG

thoracic epidural analgesia continued; supplemented by a continuous epidural infusion of ropivacaine 0.15%, 2 ml/h with fentanyl 8mcg/h.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

thoracic epidural anesthesia

thoracic epidural anesthesia following continuous thoracic epidural analgesia for mastectomy

Intervention Type PROCEDURE

mastectomy

mastectomy with/without breast reconstruction

Intervention Type PROCEDURE

Ropivacaine

Thoracic epidural anesthesia performed using 0.375% or 0.5% ropivacaine

Intervention Type DRUG

Propofol

Thoracic epidural anesthesia performed followed by sedation consisting of propofol

Intervention Type DRUG

Fentanyl

thoracic epidural analgesia continued; supplemented by a continuous epidural infusion of ropivacaine 0.15%, 2 ml/h with fentanyl 8mcg/h.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients, who scheduled for mastectomy with/without breast reconstruction

Exclusion Criteria

* The patients who had more than one abnormal preoperative clotting parameter either clinical signs of potential bleeding disorders suggested by bruising
* Petechiae, or ecchymosis, or anatomic or neurologic abnormalities
* That is, significant scoliosis or kyphosis, radyculopathy or ptosis
* Unsuccessful catheter placement (impossible to insert a catheter at two vertebral levels)
* Unsuccessful epidural anesthesia (not checkable sensory block)
* Dural perforation or intravascular catheterization
Minimum Eligible Age

20 Years

Maximum Eligible Age

80 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Soonchunhyang University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Sun Young Park

MD

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Soonchunhyang University Seoul Hospital

Seoul, , South Korea

Site Status

Countries

Review the countries where the study has at least one active or historical site.

South Korea

References

Explore related publications, articles, or registry entries linked to this study.

Park SY, Chun HR, Kim MG, Lee SJ, Kim SH, Ok SY, Cho A. Transient Horner's syndrome following thoracic epidural anesthesia for mastectomy: a prospective observational study. Can J Anaesth. 2015 Mar;62(3):252-7. doi: 10.1007/s12630-014-0284-9. Epub 2015 Jan 6.

Reference Type DERIVED
PMID: 25560203 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HS-Tepi

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.